{
  "id": 20427848,
  "title": "Marrow sets out to challenge genetic medicines for severe blood diseases",
  "url": "https://urgent.news/2026/11/17/marrow-sets-out-to-challenge-genetic-medicines-for-severe-blood",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-17T12:00:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/marrow-therapeutics-sickle-cell-beta-thalassemia-drug/874789/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Armed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta thalassemia.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}